Effects of Peanut Consumption on Adults With Metabolic Associated Fatty Liver Disease

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age30-70
SponsorHenry Ford Health System

About this trial

The aim of this randomized interventional trial is to understand the effects of peanut consumption on patients with metabolic associated fatty liver. The main goal is to investigate if patients who consume peanuts have improved liver marker tests as well as metabolic profile. We will also investigate how peanuts alter the gut microbes and liver fat content in patients with metabolic associated fatty liver.

* Participants will be randomized into intervention (peanut consumption for 12 weeks) and control (regular diet) arm. * Stool sample and blood (for biomarkers) collection across both arms at baseline and post-intervention * Daily log to be completed for tracking peanut consumption * 2-day Dietary recall at baseline, during Week 6 and Week 12 * Poat intervention Fibro scans for participants with baseline scans available

Eligibility criteria

Qualifiers

30-70 years

do not consume peanut/peanut butter/treenut/seeds > /week

at least one encounter-related (stage F0/F1) MASLD diagnosis (K76.0)

Able to understand, speak, and read English

Disqualifiers

Food allergy to peanuts or peanut-containing products

With alcohol use disorder (AUDIT screening)

Leukemia

Lymphoma

Trial design

Treatments tested in this trial

  • Peanut consumption

Treatment groups

125 Participants
are divided into 2 treatment groups

Locations

1
Henry Ford Health System48202, DetroitMichigan, United States

Sponsors and collaborators

Henry Ford Health System

Lead sponsor